AU2004262906B2 - Use of calcitonin in osteoarthritis - Google Patents

Use of calcitonin in osteoarthritis Download PDF

Info

Publication number
AU2004262906B2
AU2004262906B2 AU2004262906A AU2004262906A AU2004262906B2 AU 2004262906 B2 AU2004262906 B2 AU 2004262906B2 AU 2004262906 A AU2004262906 A AU 2004262906A AU 2004262906 A AU2004262906 A AU 2004262906A AU 2004262906 B2 AU2004262906 B2 AU 2004262906B2
Authority
AU
Australia
Prior art keywords
calcitonin
cnac
salmon
delivery agent
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004262906A
Other languages
English (en)
Other versions
AU2004262906A1 (en
Inventor
Moise Azria
Simon David Bateman
Claus Christiansen
Shoufeng Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Nordic Bioscience AS
Original Assignee
Novartis AG
Nordic Bioscience AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004262906(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, Nordic Bioscience AS filed Critical Novartis AG
Publication of AU2004262906A1 publication Critical patent/AU2004262906A1/en
Application granted granted Critical
Publication of AU2004262906B2 publication Critical patent/AU2004262906B2/en
Priority to AU2008202879A priority Critical patent/AU2008202879B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2004262906A 2003-07-23 2004-07-22 Use of calcitonin in osteoarthritis Ceased AU2004262906B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008202879A AU2008202879B2 (en) 2003-07-23 2008-06-30 Use of calcitonin in osteoarthritis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48940003P 2003-07-23 2003-07-23
US60/489,400 2003-07-23
PCT/EP2004/008210 WO2005014031A1 (en) 2003-07-23 2004-07-22 Use of calcitonin in osteoarthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008202879A Division AU2008202879B2 (en) 2003-07-23 2008-06-30 Use of calcitonin in osteoarthritis

Publications (2)

Publication Number Publication Date
AU2004262906A1 AU2004262906A1 (en) 2005-02-17
AU2004262906B2 true AU2004262906B2 (en) 2008-04-03

Family

ID=34135096

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2004262906A Ceased AU2004262906B2 (en) 2003-07-23 2004-07-22 Use of calcitonin in osteoarthritis
AU2008202879A Ceased AU2008202879B2 (en) 2003-07-23 2008-06-30 Use of calcitonin in osteoarthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008202879A Ceased AU2008202879B2 (en) 2003-07-23 2008-06-30 Use of calcitonin in osteoarthritis

Country Status (22)

Country Link
US (3) US7749954B2 (https=)
EP (2) EP1651249B1 (https=)
JP (2) JP4716987B2 (https=)
KR (1) KR101070036B1 (https=)
CN (1) CN1856321B (https=)
AU (2) AU2004262906B2 (https=)
BR (1) BRPI0412265A (https=)
CA (1) CA2532565C (https=)
ES (2) ES2398237T3 (https=)
IL (2) IL173002A (https=)
IS (1) IS8316A (https=)
MA (1) MA27929A1 (https=)
MX (1) MXPA06000807A (https=)
NO (1) NO330867B1 (https=)
NZ (1) NZ544645A (https=)
PL (2) PL1651249T3 (https=)
PT (2) PT1651249E (https=)
RU (1) RU2368390C2 (https=)
TN (1) TNSN06022A1 (https=)
TW (1) TWI343816B (https=)
WO (1) WO2005014031A1 (https=)
ZA (1) ZA200600373B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005080A (es) * 2004-05-27 2005-11-30 Aspid S A De C V Una composicion moduladora de la inflamacion articular cronica a base de colagena-polivinilpirrolidona.
PE20100241A1 (es) 2005-09-19 2010-04-16 Emisphere Tech Inc Formas cristalinas de la sal di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
RU2469709C2 (ru) 2005-11-17 2012-12-20 Новартис Аг Фармацевтическая композиция
AU2007289344B2 (en) 2006-08-31 2011-04-14 Novartis Ag Pharmaceutical compositions comprising hGH for oral delivery
KR20150091536A (ko) * 2007-03-02 2015-08-11 노파르티스 아게 칼시토닌의 경구 투여
EP2460515B1 (en) * 2007-08-09 2017-03-08 Novartis AG Oral calcitonin compositions and applications thereof
NZ585080A (en) 2007-11-02 2012-05-25 Emisphere Tech Inc Composition comprising Vitamin B12 and N-[8-(2-hydroxybenzoyl) amino ]caprylic acid and salts thereof for treating Vitamin B12 deficiency
RU2494755C2 (ru) 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
RU2537181C2 (ru) * 2009-03-12 2014-12-27 Нордик Байосайенс А/С Лечение диабета и метаболического синдрома
ES2583259T3 (es) 2009-12-01 2016-09-20 Novo Nordisk A/S Nuevas liasas alfa-amidantes de peptidil alfa-hidroxiglicina
US20120071410A1 (en) 2010-09-21 2012-03-22 Unigene Laboratories Inc. Calcitonin products and therapies for treating inflammatory or degenerative diseases
BR112014010701A2 (pt) 2011-11-02 2020-06-23 Keybioscience Ag Uso de um peptídeo
EP2773365B1 (en) 2011-11-02 2016-07-20 KeyBioscience AG Peptide analogs for treating diseases and disorders
ES2797452T3 (es) * 2012-03-16 2020-12-02 Fertility Innovations Ltd Procesamiento de espermatozoides
ES2660788T3 (es) 2013-11-14 2018-03-26 Keybioscience Ag Miméticos de la calcitonina para el tratamiento de enfermedades y trastornos
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190036903A (ko) 2017-09-28 2019-04-05 (주)휴럼 리트세노라이드를 유효성분으로 하는 염증과 골관절염에 대한 예방 및 치료용 약학 조성물
US11274158B2 (en) * 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
CN108586601B (zh) * 2018-05-14 2021-07-27 四川大学 一种骨靶向性鲑鱼降钙素及其制备方法
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
JP2023515886A (ja) 2020-03-02 2023-04-14 マジック リープ， インコーポレイテッド 没入型のオーディオプラットフォーム

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
WO2000059863A1 (en) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US608618A (en) 1898-08-09 Thomas millen
HU203204B (en) 1987-09-15 1991-06-28 Sandoz Ag Process for producing suppository containing calcitonin and taurocholic acid
JP3501471B2 (ja) 1992-06-15 2004-03-02 旭化成ファーマ株式会社 カルシトニン類の安定化組成物および安定化法
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
GB9623205D0 (en) * 1996-11-07 1997-01-08 Eurand Int Novel pharmaceutical compositions
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
US20020012459A1 (en) * 2000-06-22 2002-01-31 Chips Brain Co. Ltd. Method and apparatus for detecting stereo disparity in sequential parallel processing mode
AU2001285489A1 (en) 2000-08-29 2002-03-13 Nobex Corporation 5-ASA derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
EP1404654A4 (en) 2000-10-25 2008-12-03 Smithkline Beecham Corp CALCILYTIC COMPOUNDS
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
EP1420827B8 (en) 2001-08-17 2009-12-23 Novartis AG 5-cnac as oral delivery agent for parathyroid hormone fragments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
WO2000059863A1 (en) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Consoli G et al, 1986, Clin. Ter. 118:37-47 *
Gospodinoff A et al, 1984, Clinica Terapeutica, 110(2):129-133 *
Guggi & Bernkop-Schnurch, 2003, Int. J. Pharm. 252:187-196 *
Lee Y et al, 2000, Advanced Drug Delivery Reviews, 42:225-238 *
Mongiorgi R et al, 1992, Boll. Soc. It. Biol. Sper. 68(2):85-89 *
Smethurst M et al 1981, Acta Vitaminol. Enzymol, 3(1):8-11. *

Also Published As

Publication number Publication date
WO2005014031A1 (en) 2005-02-17
EP2316473A1 (en) 2011-05-04
NZ544645A (en) 2009-04-30
IS8316A (is) 2006-02-21
JP2006528152A (ja) 2006-12-14
AU2008202879B2 (en) 2012-05-24
ES2398237T3 (es) 2013-03-14
US7749954B2 (en) 2010-07-06
RU2006105479A (ru) 2007-09-10
CA2532565A1 (en) 2005-02-17
ZA200600373B (en) 2007-01-31
IL227988A (en) 2016-10-31
KR101070036B1 (ko) 2011-10-04
ES2436152T3 (es) 2013-12-27
TNSN06022A1 (en) 2007-10-03
NO330867B1 (no) 2011-08-01
JP2011121987A (ja) 2011-06-23
CN1856321A (zh) 2006-11-01
JP4716987B2 (ja) 2011-07-06
PL1651249T3 (pl) 2013-04-30
EP2316473B1 (en) 2013-08-21
US20100278881A1 (en) 2010-11-04
CA2532565C (en) 2012-05-08
BRPI0412265A (pt) 2006-09-05
MA27929A1 (fr) 2006-06-01
US20060194722A1 (en) 2006-08-31
PT1651249E (pt) 2012-12-21
KR20060034298A (ko) 2006-04-21
RU2368390C2 (ru) 2009-09-27
MXPA06000807A (es) 2006-08-23
EP1651249A1 (en) 2006-05-03
IL173002A (en) 2013-09-30
CN1856321B (zh) 2012-10-03
US20140271735A1 (en) 2014-09-18
PT2316473E (pt) 2013-09-20
IL173002A0 (en) 2006-06-11
PL2316473T3 (pl) 2014-05-30
AU2004262906A1 (en) 2005-02-17
HK1152229A1 (en) 2012-02-24
TW200518769A (en) 2005-06-16
HK1089935A1 (en) 2006-12-15
NO20060890L (no) 2006-04-24
AU2008202879A1 (en) 2008-07-24
TWI343816B (en) 2011-06-21
US8765675B2 (en) 2014-07-01
EP1651249B1 (en) 2012-09-12
IL227988A0 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
AU2008202879B2 (en) Use of calcitonin in osteoarthritis
JP6118107B2 (ja) Ｒａの処置のためのカルシトニンの使用
KR20080066958A (ko) 약제학적 조성물
HK1089935B (en) Use of calcitonin in osteoarthritis
HK1152229B (en) Use of calcitonin in osteoarthritis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired